A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

Show other versions (1)

The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.

Bibliographic Details
Main Authors:	B. B. Gegenava, O. M. Drapkina
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	aldosterone heart failure atrial fibrillation chronic renal failure albuminuria eplerenone spironolactone gynecomastia
Online Access:	https://www.rpcardio.online/jour/article/view/146

Similar Items

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
by: Nappi J, et al.
Published: (2011-06-01)

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure
by: C McKenna, et al.
Published: (2010-05-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Ocena skuteczności i bezpieczeństwa farmakoterapii inhibitorami aldosteronu w niewydolności serca = Evaluation of the efficacy and safety of pharmacotherapy using aldosterone antagonists in heart failure
by: Agata Tarczykowska, et al.
Published: (2015-07-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
by: Argen Mamazhakypov, et al.
Published: (2023-01-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
by: Fernet M, et al.
Published: (2018-09-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
by: Camila Q. Felipe, et al.
Published: (2022-06-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
by: Athanasakis K, et al.
Published: (2016-10-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats
by: Xue Wang, et al.
Published: (2020-08-01)

EVIDENCE-BASED USE OF EPLERENONE
by: S. R. Gilyarevski, et al.
Published: (2014-07-01)

EVIDENCE-BASED USE OF EPLERENONE
by: S. R. Gilyarevski, et al.
Published: (2014-07-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
by: Natalia V. Safronova, et al.
Published: (2022-01-01)

New Clinical Aspects of Eplerenone Use in Clinical Practice
by: S. R. Gilyarevskiy, et al.
Published: (2018-09-01)

Hyperaldosteronemia as a risk factor of renal dysfunction in patients with heart failure with preserved ejection fraction
by: A. N. Shevelok
Published: (2020-12-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats
by: Ashraf Taye, et al.
Published: (2012-05-01)

Ocena skuteczności i bezpieczeństwa farmakoterapii inhibitorami aldosteronu w niewydolności serca = Evaluation of the efficacy and safety of pharmacotherapy using aldosterone antagonists in heart failure
by: Agata Tarczykowska, et al.
Published: (2015-07-01)

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure
by: I. V. Zhirov, et al.
Published: (2015-12-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
by: Manolis AA, et al.
Published: (2019-12-01)

Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
by: Eduard Shantsila, et al.
Published: (2020-07-01)

Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta‐Analysis, and Meta‐Regression to Identify Modifying Factors
by: Joachim Alexandre, et al.
Published: (2019-11-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Influence of Different Treatment Strategies on New‐Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort‐Based Study
by: Chien‐Ting Pan, et al.
Published: (2020-03-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy
by: Katrin Fasler, et al.
Published: (2021-05-01)

Aldosterone Excess Induced Mitochondria Decrease and Dysfunction via Mineralocorticoid Receptor and Oxidative Stress In Vitro and In Vivo
by: Cheng-Hsuan Tsai, et al.
Published: (2021-08-01)

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug
by: Iwona Dams, et al.
Published: (2017-08-01)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
by: Eduard Shantsila, et al.
Published: (2020-09-01)

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature
by: Irini Chatziralli, et al.
Published: (2018-09-01)

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division
by: Andrea Vecchiola, et al.
Published: (2020-04-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
by: Pascal R. D. Clephas, et al.
Published: (2023-04-01)